MX2007001916A - Uso de la funci??n inmunosupresora de una prote??na auxiliar del virus de inmunodeficiencia humana o de simio para la preparaci??n de una vacuna. - Google Patents

Uso de la funci??n inmunosupresora de una prote??na auxiliar del virus de inmunodeficiencia humana o de simio para la preparaci??n de una vacuna.

Info

Publication number
MX2007001916A
MX2007001916A MX2007001916A MX2007001916A MX2007001916A MX 2007001916 A MX2007001916 A MX 2007001916A MX 2007001916 A MX2007001916 A MX 2007001916A MX 2007001916 A MX2007001916 A MX 2007001916A MX 2007001916 A MX2007001916 A MX 2007001916A
Authority
MX
Mexico
Prior art keywords
hiv nef
mutated hiv
modulating immunity
modulating
immunity
Prior art date
Application number
MX2007001916A
Other languages
English (en)
Inventor
Martial Renard
Marianne Mangeney
Thierry Heidmann
Original Assignee
Ct Nat De La Rech Scentifique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Nat De La Rech Scentifique filed Critical Ct Nat De La Rech Scentifique
Publication of MX2007001916A publication Critical patent/MX2007001916A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/161—HIV-1 ; HIV-2 gag-pol, e.g. p55, p24/25, p17/18, p7, p6, p66/68, p51/52, p31/34, p32, p40
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/162—HIV-1 ; HIV-2 env, e.g. gp160, gp110/120, gp41, V3, peptid T, CD4-Binding site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C07K14/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
    • G01N2333/155—Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
    • G01N2333/16—HIV-1, HIV-2
    • G01N2333/163—Regulatory proteins, e.g. tat, nef, rev, vif, vpu, vpr, vpt, vpx

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invencion se refiere al uso de una mutacion de al menos un aminoacido en el dominio inmunosupresor de proteina auxiliar de VIH o SIV, para modular la propiedad inmunosupresora de dicha proteina.
MX2007001916A 2004-08-17 2005-08-17 Uso de la funci??n inmunosupresora de una prote??na auxiliar del virus de inmunodeficiencia humana o de simio para la preparaci??n de una vacuna. MX2007001916A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04292056 2004-08-17
PCT/EP2005/008907 WO2006018289A1 (en) 2004-08-17 2005-08-17 Mutated hiv nef for modulating immunity

Publications (1)

Publication Number Publication Date
MX2007001916A true MX2007001916A (es) 2007-07-11

Family

ID=34931346

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007001916A MX2007001916A (es) 2004-08-17 2005-08-17 Uso de la funci??n inmunosupresora de una prote??na auxiliar del virus de inmunodeficiencia humana o de simio para la preparaci??n de una vacuna.

Country Status (13)

Country Link
US (1) US8795685B2 (es)
EP (2) EP1778282B1 (es)
JP (1) JP4926060B2 (es)
CN (1) CN101027084B (es)
AU (1) AU2005274324B2 (es)
BR (1) BRPI0514447B8 (es)
CA (1) CA2577183C (es)
DK (1) DK1778282T3 (es)
ES (1) ES2572132T3 (es)
IL (1) IL180921A (es)
MX (1) MX2007001916A (es)
WO (1) WO2006018289A1 (es)
ZA (1) ZA200701180B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104932A2 (en) * 2006-03-10 2007-09-20 Peptcell Limited Peptides of regulatory or accessory proteins of hiv, compositions and the utilization thereof
MX350689B (es) 2011-12-07 2017-09-13 Viroxis S A S Proteinas env lentivirales mutadas y su uso como farmacos.
US9777042B2 (en) * 2011-12-15 2017-10-03 Morehouse School Of Medicine Method of purifying HIV/SIV Nef from exosomal fusion proteins
CN109836480B (zh) * 2017-11-29 2023-03-14 陈松明 一种重组免疫抑制蛋白
TW202020146A (zh) * 2018-07-26 2020-06-01 大陸商南京傳奇生物科技有限公司 含nef之t細胞及其產生方法
KR20220047277A (ko) 2019-07-16 2022-04-15 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
JP2024502658A (ja) 2021-01-13 2024-01-22 ヴィロキシ 麻疹－ｈｉｖ又は麻疹－ｈｔｌｖワクチン
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5079342A (en) * 1986-01-22 1992-01-07 Institut Pasteur Cloned DNA sequences related to the entire genomic RNA of human immunodeficiency virus II (HIV-2), polypeptides encoded by these DNA sequences and use of these DNA clones and polypeptides in diagnostic kits
EP0283327B1 (fr) * 1987-01-16 1997-06-25 Institut Pasteur Peptides ayant des propriétés immunologiques de HIV-2
US5221610A (en) * 1988-05-26 1993-06-22 Institut Pasteur Diagnostic method and composition for early detection of HIV infection
US5223423A (en) * 1989-03-31 1993-06-29 United States Of America Characterization of replication competent human immunodeficiency type 2 proviral clone hiv-2sbl/isy
DE69434151D1 (de) * 1993-05-18 2004-12-30 Biomolecular Res Inst Ltd Therapeutische inhaltsstoffe
US5519114A (en) * 1993-10-29 1996-05-21 University Of Florida Research Foundation, Inc. Retroviral superantigens, superantigen peptides, and methods of use
FR2756843B1 (fr) * 1996-12-09 1999-01-22 Inst Nat Sante Rech Med Souches de vih-1 non-m non-o, fragments et applications
ES2250151T3 (es) 1999-06-29 2006-04-16 Glaxosmithkline Biologicals S.A. Uso de cpg como adyuvante de vacuna contra vih.
CA2439990A1 (en) 2001-03-01 2002-09-12 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention, Technology Transfer Office Immunogenic hiv peptides for use as reagents and vaccines
GB0118367D0 (en) 2001-07-27 2001-09-19 Glaxosmithkline Biolog Sa Novel use
US7312305B2 (en) * 2002-03-20 2007-12-25 Morehouse School Of Medicine Tumor cytotoxicity induced by modulators of the CXCR4 receptor

Also Published As

Publication number Publication date
ZA200701180B (en) 2008-11-26
IL180921A (en) 2013-07-31
EP2420248A1 (en) 2012-02-22
BRPI0514447B8 (pt) 2021-05-25
BRPI0514447A (pt) 2008-06-10
JP4926060B2 (ja) 2012-05-09
CA2577183C (en) 2014-02-18
CN101027084A (zh) 2007-08-29
AU2005274324A1 (en) 2006-02-23
ES2572132T3 (es) 2016-05-30
WO2006018289A1 (en) 2006-02-23
DK1778282T3 (en) 2016-06-06
EP1778282A1 (en) 2007-05-02
EP1778282B1 (en) 2016-03-30
US20080220008A1 (en) 2008-09-11
CA2577183A1 (en) 2006-02-23
AU2005274324B2 (en) 2011-06-23
US8795685B2 (en) 2014-08-05
IL180921A0 (en) 2007-07-04
CN101027084B (zh) 2012-02-22
JP2008509691A (ja) 2008-04-03
BRPI0514447B1 (pt) 2021-03-02

Similar Documents

Publication Publication Date Title
MX2007001916A (es) Uso de la funci??n inmunosupresora de una prote??na auxiliar del virus de inmunodeficiencia humana o de simio para la preparaci??n de una vacuna.
ATE373081T1 (de) Zelllinie
HK1173169A1 (en) Dimercaptan terminated polythioether polymers and methods for making and using the same
AU303137S (en) Bottle
DE60332774D1 (de) Verbesserte sso7-polymerase-konjugat-proteine
GEP20094644B (en) Retinyl derivatives, compositions thereof and assays for treating retinol-related diseases
WO2006089045A3 (en) Methods and compositions for determining hypersusceptibility of hiv-1 to non-nucleoside reverse transcriptase inhibitors
MX2007002679A (es) Compuestos quimicos.
NO20090047L (no) Anti-DLL4-antistoffer og fremgangsmater for anvendelse av disse
DE602007004999D1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen-derivate als orexinrezeptor-antagonisten
MX2007006830A (es) Porciones de la familia del polipeptido pancreatico, polipeptidos y metodos que comprenden las mismas.
WO2007081419A3 (en) Compositions and methods related to anti-fgf agents
WO2006134190A3 (es) Agentes y métodos basados en el uso del dominio eda de la fibronectina
AU304950S (en) Closure
TW200609664A (en) Aqueous edge bead remover
EA200702201A1 (ru) Рофлумиласт для лечения лёгочной гипертензии
AU306269S (en) Toothbrush
CA115998S (en) Holder for a scrubber
AU301994S (en) Writing utensil
程林 Make sure you are not doing other people's work
TR200503753U (tr) Barel kırma aparatlarında yenilik
TW200617021A (en) Isolated photoprotein aequorin y89f, and its use
张代伟 et al. The Original Swiss Bottle: SIGG
卞纯宗 Wallpaper 76
温光宇 Gorillas Branch out into Tool Use

Legal Events

Date Code Title Description
FA Abandonment or withdrawal